PreserVision and AREDS2: What the Name on the Box Guarantees

PreserVision comes up more than any other name in searches about AREDS2, which makes sense: it is Bausch + Lomb's eye-vitamin line and the one most closely associated with these formulations in most markets. How it sits against the other products on the shelf is a comparison of the published labels.

The interesting question is not whether it is good. It is what people think the name on the box is telling them, because there is a consistent gap there.

What the name does and does not signal

Worth separating carefully, because both halves are true at once.

This is not an accusation against any particular company. It is a description of how supplement labelling works in most jurisdictions, where products are not pre-approved the way medicines are and the burden of checking falls on the buyer.

How to verify any of them, including this one

The check is the same regardless of the name on the front. Turn the bottle over and compare the panel with the formulation AREDS2 tested: vitamin C 500 mg, vitamin E 400 IU, lutein 10 mg, zeaxanthin 2 mg, zinc 80 mg, copper 2 mg.

1. 01Are all six there? Copper is the one most often missing, and it is the one that matters most, because it is in the formula to stop the zinc causing a copper deficiency.
2. 02Is beta-carotene absent? Its presence means either the older AREDS formula or a product assembled without attention. For anyone who has ever smoked this is a safety issue rather than a quality one.
3. 03Do the amounts land near the trial? Note that products differ on zinc, some at 80 mg and some at 25 mg. AREDS2 tested both and found no difference, so this particular variation is not a quality signal.
4. 04How many units per day? Reaching the full amounts often takes two a day rather than one. This changes both the real cost and whether you will keep it up.

We set the whole checklist out, grouped by how much each factor actually changes, in how to choose an AREDS2 supplement.

How often do eye-care professionals recommend it?

This gets asked a lot, and the honest answer is that nobody knows in any rigorous sense.

There is no public register of supplement recommendations, no prescription record to audit, and no reliable survey we would be willing to cite as a number. Anyone quoting you a market-share figure or a percentage of clinicians is either extrapolating from sales data or repeating marketing. We are not going to invent one.

What can be said usefully is what the recommendation is actually about. When an ophthalmologist or optometrist suggests an AREDS2 supplement, they are endorsing the formulation, because that is what the evidence attaches to. Brand familiarity plays a part, as it does everywhere in medicine, and the most recognised name is the one most likely to be named in a short consultation. That is not the same as a judgement that other compliant products are inferior.

The question that comes before all of this

Everything above assumes the supplement is appropriate for you at all, and for most people looking at these shelves it is not.

Both AREDS trials found benefit only in people who already have intermediate age-related macular degeneration, or advanced AMD in one eye. For people with no AMD or only very early changes, they showed nothing. Intermediate AMD is typically symptomless, so you cannot establish it from how your vision feels. It takes a dilated examination and a direct question about what stage you are at.

If the answer is that your retina looks healthy, you have been told the supplement would do nothing for you, which is worth far more than the price of any bottle. We cover who the evidence supports in full.